PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

MedImmune Limited

USPTO PatentsView assignee record — 327 granted patents across 28 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Explore the portfolio See the ranking
327
Total patents granted
28
CPC technology areas
17.4
Avg claims per patent
-2%
5-year filing velocity

Portfolio overview

MedImmune Limited has been granted 327 US utility patents between 2015 and 2025, placing MedImmune Limited at rank #1,293 across all assignees tracked by PlainPatent. This portfolio spans 28 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.4 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, MedImmune Limited is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 54.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 162 grants, compared with 165 in the 2015–2019 window — a -2% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. MedImmune Limited's 17.4 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 28 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark MedImmune Limited against peers pursuing similar technology classes.

How does MedImmune compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows MedImmune holds 327 patents — placing it at rank #1,293 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

USPTO utility patent grants by year · 2015–2025

1020304050 20152016201720182019202020212022202320242025 13
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
MedImmune Limited patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 27 8.3%
2016 31 9.5%
2017 29 8.9%
2018 45 13.8%
2019 33 10.1%
2020 44 13.5%
2021 28 8.6%
2022 26 8.0%
2023 33 10.1%
2024 18 5.5%
2025 13 4.0%

Which technologies does MedImmune Limited patent most?

Top 15 of 28 technology areas

Patent Moat Analysis

Portfolio Volume Moderate
Tech Breadth Multi-domain
Claim Depth Standard
Velocity Declining

Where it ranks

Overall rank by patents

#1,293

Across all tracked assignees

Innovation Score

54.1 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does MedImmune Limited hold?
MedImmune Limited holds 327 US granted patents filed between 2015 and 2025, spanning 28 technology areas.
What is MedImmune Limited's Innovation Score?
MedImmune Limited has an Innovation Score of 54.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does MedImmune Limited focus on?
MedImmune Limited's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 283 patents. The company has filed patents in 28 CPC subclasses total.
Is MedImmune Limited's patent filing rate increasing or decreasing?
MedImmune Limited's recent filing velocity is -2% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for MedImmune Limited's patents?
MedImmune Limited's patents average 17.4 claims each. This falls within the standard range, providing solid legal coverage.
How is the MedImmune Limited patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

How Innovation Score Works

Understand the four dimensions behind the composite score
How to Read Patent Data

Plain-English guide to CPC codes, claims, and metrics
Patent Moat Analysis

How companies use patents as competitive barriers

Explore the patent dataset

A61P technology

MedImmune Limited's primary CPC class — all holders and yearly trends
Top 50 patent holders

See where MedImmune Limited ranks among the largest US patent assignees
All technology classes

Browse every CPC technology area by patent activity
How the score works

The four dimensions behind the Innovation Score

Related

All companies → | All technologies → | Rankings →
Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology — how this data is sourced, computed, and verified.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope